2008-05-20 23:33:45 -
www.researchandmarkets.com - Research and Markets (www.researchandmarkets.com/reports/c92391) has announced the addition of Spain Pharmaceuticals and Healthcare Report Q2 2008 to their offering.
The Spain Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Spain's pharmaceuticals and healthcare industry.
Spain's drug market was worth US$16.58bn in 2007 and is forecast to reach US$18.9bn in value by 2012, representing
a compound annual growth rate (CAGR) of 2.65%, which is hardly stellar but is perhaps understandable in light of the period of economic cooling that the country is likely to experience in the next few years. The generics sector is showing the most robust growth, which should reach a value of US$1.04bn by 2012, however the fact that it is growing from a low base is limiting its impact on the overall market.
In Q208, the author has included Spain's medical device sector in its coverage for the first time. Following rapid growth in the early part of the decade, the market reached an estimated value of US$3.9bn in 2007. Although the sector is still expanding at a brisk pace in local currency terms, exchange rate considerations have affected the market in US dollar terms. However, for 2006-2012, the author forecasts that there will be a CAGR of around 10% in US dollar value, driven by the continuing incorporation of new technology and the demands of an aging population.
Spanish drugmaker Zeltia announced in December 2007 that it is planning to float its neurological disease arm Neuropharma on the stock market. The author believes a public float could be a good source of new capital and may spark further listings in the Spanish drug sector. Canadian generics firm Apotex has made its second acquisition in Europe in the space of a month, snapping up Spain's Lareq Pharma, for an undisclosed fee, from parent company Industria Quimica Y Farmaceutica.
Spain remains at the bottom of the business environment rankings due to sluggish growth and a relatively low per capita spend on pharmaceuticals. However, this last factor could actually act as an incentive for investors as it means that there remains untapped capacity in the country and potential upside, especially in underdeveloped areas such as generics.
Content Outline:
Executive Summary
Spain: Pharmaceutical And Healthcare Industry SWOT
Spain Political SWOT
Spain Economic SWOT
Pharmaceutical Business Environment Ratings
Table: Business Environment Rankings
Spain - Market Summar
Regulatory Regime
Intellectual Property Issues
Pricing And Reimbursement Issues
Table: Timeline - Spains Pharmaceutical Pricing Reforms
Price Cut On Older Drugs
Reference Pricing System
Industry Reaction
Parallel Trade
Industry Developments
Foreign Sector
Generics Sector
Indigenous Manufacturing Sector
Research Sector Developments
Table: Firms Active In Nanofarma Consortium
Government Investment
Industry Forecast Sce34
Overall Market Forecast
Table: Spain's Drug Market Forecast Indicators
Table: Spain's Health Expenditure Forecast Indicators
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Table: Spain Economic Activity
Patented Market Forecast
Table: Spain's Patented Drugs Market Forecast Indicators (US$mn unless otherwise stated)
OTC Market Forecast
Table: Spain's OTC Market Forecast Indicators (US$mn unless otherwise stated)
Generics Market Forecast
Table: Spain's Generics And Branded Market Forecast Indicators
Export/Import Forecast
Table: Pharmaceutical Trade Indicators (US$mn)
Medical Devices
Spain Medical Device Market Forecast
Competitive Landscape
Retail Market
Manufacturers
Company Profiles
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Pfizer
Novartis
Sanofi-Aventis
Merck & Co
Indigenous Manufacturers
Almirall Prodesfarma
Dr Esteve
Our Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Companies Mentioned:
- Almirall Prodesfarma
- Dr Esteve
- GlaxoSmithKline (GSK)
- Merck & Co
- Novartis
- Pfizer
- Sanofi-Aventis
For more information visit
www.researchandmarkets.com/reports/c92391
Research and Markets
Laura Wood, Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com 
